Search Results
Your search for all items matches 36011 pages
Showing 1 - 50ASCO and Conexiant Launch ASCO AI in Oncology
The American Society of Clinical Oncology (ASCO®) and Conexiant today announced the launch of ASCO AI in Oncology, a premier digital destination designed to help oncology professionals navigate the transformative role of artificial intelligence (AI) in cancer care. Launching this initiative marks...
Olaparib in Metastatic Breast Cancer With Germline Mutations in PALB2 or Somatic Mutations in BRCA
As reported in the Journal of Clinical Oncology by Tung et al, findings in expansion cohorts of the phase II Translational Breast Cancer Research Consortium (TBCRC) 048 study showed that olaparib was active in patients with metastatic breast cancer with germline PALB2 mutations (gPALB2m) and in...
A New Risk Model for Esophagectomy Draws on the STS National Database
A nationwide, real-world analysis using the Society of Thoracic Surgeons (STS) General Thoracic Surgery Database (GTSD) from 2012 to 2023 evaluated over 16,000 adults who underwent esophagectomy for primary esophageal cancer to develop and validate a long-term all-cause mortality risk model. The...
Ultra–Low-Dose Immunotherapy in Relapsed or Refractory Solid Tumors
In an Indian single-center phase III trial (DELII) reported in the Journal of Clinical Oncology, Noronha et al found that “ultra–low-dose” immune checkpoint inhibitor therapy with the PD-1 inhibitor nivolumab was associated with improved overall survival vs standard chemotherapy among patients with ...
Self-Acupressure May Ease Fatigue in Ovarian Cancer Survivors
In a phase III single-blind randomized clinical trial reported in JAMA Network Open, Zick et al found that self-acupressure—taught via a mobile app—provided a safe, low-cost approach for managing fatigue in ovarian cancer survivors. “In this randomized clinical trial, true self-acupressure and sham ...
HPV Testing During Cervical Cancer Screening: Potential ‘Convenient and Noninvasive’ Method
Testing menstrual blood for human papillomavirus (HPV) could be a “robust alternative or replacement” for current cervical cancer screening by a clinician, according to findings from a Chinese study published by Tian et al in The BMJ. The researchers say using menstrual blood for HPV testing is...
Guidelines Harmonize Pan-Tumor Pathologic Response to Neoadjuvant Therapy
The first unified, pan-tumor guideline framework has been released for how pathologists should evaluate and score response in the neoadjuvant setting. These consensus guidelines, which were a joint effort by the Society for Immunotherapy of Cancer's (SITC) Pan-tumor Harmonization of Pathologic...
Tissue-Free ctDNA and Outcomes in Patients With Colorectal Cancer Receiving FOLFOX-Based Adjuvant Therapy
In a study reported in the Journal of Clinical Oncology, Sinicrope et al found that a tissue-free circulating tumor DNA (ctDNA) assay had strong prognostic value in patients receiving FOLFOX (fluorouracil, leucovorin, and oxaliplatin)-based adjuvant therapy for stage III colorectal cancer. Study...
Ultraprocessed Food Associated With Increased Mortality Risk in Cancer Survivors
Consumption of higher quantities of ultraprocessed food was associated with increased all-cause and cancer mortality rates in cancer survivors, irrespective of the quality of their diet, according to findings published in Cancer Epidemiology, Biomarkers & Prevention. “These results suggest...
A Paradigm Shift In Treating Adult AML?
The scientific revolution in determining the genetic basis of cancer is finally bearing fruit in hematologic neoplasms such as acute myeloid leukemia (AML), where over the past decade a number of effective new drugs have expanded our armamentarium and provided effective—and in some cases...
Lymph Node Examination Should be Expanded to Accurately Assess Metastasis in NSCLC, Research Says
Breakthrough research presented at the 2026 Society of Thoracic Surgeons (STS) Annual Meeting shows that additional lymph node evaluation is needed during surgery for non–small cell lung cancer (NSCLC) to accurately identify cancer spread (Abstract A-1588). Globally, surgical standards vary on the...
FDA Provides Safety Labeling Update for Capecitabine and Fluorouracil on Risks Associated With DPD Deficiency
The U.S. Food and Drug Administration (FDA) has provided communication to increase awareness of recent updates to the product labeling of capecitabine (Xeloda) and fluorouracil—indicated for colorectal, breast, gastric/esophageal/gastroesophageal, and pancreatic cancers—related to risks associated...
VTE During Perioperative Therapy in Resectable and Borderline Resectable Pancreatic Cancer
As reported in the Journal of Clinical Oncology by Willems et al, venous thromboembolism (VTE) occurred in a high proportion of patients with resectable/borderline resectable pancreatic ductal adenocarcinoma receiving neoadjuvant FOLFOXIRI (5-fluorouracil, leucovorin, irinotecan, and oxaliplatin)...
Agent Orange Exposure Linked With Risk for Acral Melanoma in Veterans
Exposure to Agent Orange in U.S. veterans was associated with an increased odds of developing acral melanoma compared with controls with and without cutaneous melanoma, according to findings published in JAMA Dermatology. The study authors suggested that there is a need for continued investigation ...
Colorectal Cancer Liver Metastases: Transplant or Resect?
Colorectal metastases isolated to the liver no longer portend a universally fatal outcome. In 2024, the TransMet study1demonstrated that liver transplantation in select patients could be life-saving—thus changing the treatment paradigm—but so can surgical resection when appropriately applied....
New European Project Cluster EARLYSCAN Launched to Advance Early Detection of Heritable Cancers
A new European collaboration cluster, EARLYSCAN (Early Screening & Hereditary Cancer Awareness Network), has been launched to strengthen prevention and early detection strategies for heritable cancers. The cluster brings together three Horizon Europe–funded projects: SHIELD, DISARM, and...
First-Line mFOLFOXIRI Plus Panitumumab for RAS/BRAF Wild-Type Metastatic Colorectal Cancer
As reported in the Journal of Clinical Oncology by Conca et al, the final results of the Italian phase III TRIPLETE trial showed that first-line mFOLFOXIRI (modified fluorouracil, leucovorin, oxaliplatin, irinotecan) plus panitumumab improved overall survival vs mFOLFOX (modified fluorouracil,...
Metastasis-Directed Therapy for Oligometastatic Prostate Cancer
Metastasis-directed therapy significantly improved progression-free survival, radiologic progression–free survival, and castration resistance–free survival in patients with oligometastatic prostate cancer, according to a new study published by Tang et al in The Lancet Oncology. The study is a...
WHO Analysis Finds Nearly 40% of Global Cancer Cases Attributable to Modifiable Risk Factors
Almost 40% of all new cancer cases could be attributed to at least one of 30 modifiable risk factors, according to a new global analysis from the World Health Organization (WHO) and its International Agency for Research on Cancer (IARC). The analysis of preventable cancers was published in Nature...
Joseph A. Sparano, MD, on Multimodal AI Models for Predicting Breast Cancer Recurrence
Joseph A. Sparano, MD, of the Icahn School of Medicine at Mount Sinai, discusses the performance of experimental multimodal artificial intelligence (AI) models integrating clinical, molecular, and histopathologic features to provide prognostic information for early and late recurrence using primary ...
Jame Abraham, MD, FACP, on HER2-Positive Metastatic Breast Cancer: Choosing a Regimen in Clinical Practice
Jame Abraham, MD, FACP, puts findings from several trials in HER2-positive breast cancer into context, including HER2CLIMB, which investigated tucatinib, trastuzumab, and capecitabine in pretreated patients with metastatic disease; DESTINY Breast-09, which evaluated fam-trastuzumab deruxtecan-nki...
ASH 2025: Highlights in Relapsed/Refractory Multiple Myeloma
“Dripping water hollows out stone, not through force but through persistence.” – Ovid The 2025 American Society of Hematology (ASH) Annual Meeting & Exposition delivered multiple practice-changing datasets surrounding T-cell–redirecting therapies in relapsed or refractory multiple myeloma....
World Cancer Day 2026: UICC’s Campaign ‘United by Unique’
As the organizer of World Cancer Day on February 4, the Union for International Cancer Control (UICC) is mobilizing organizations and individuals worldwide to ensure that the voices of people affected by cancer are heard and drive a new vision of cancer care. Now in its second year, the World...
Addition of Palbociclib to Standard Therapy in Hormone Receptor–Positive, HER2-Positive Metastatic Breast Cancer
In a phase III trial (PATINA) reported in The New England Journal of Medicine, Metzger et al found that the addition of palbociclib to anti-HER2 and endocrine therapies significantly prolonged progression-free survival in patients with hormone receptor–positive, HER2-positive metastatic breast...
Oxybutynin May Improve ADT-Induced Hot Flashes in Patients With Prostate Cancer
The use of oxybutynin led to statistically significant reductions in the number of hot flashes per day compared with placebo for men with prostate cancer receiving androgen-deprivation therapy (ADT), according to findings from the Alliance A222001 trial published in the Journal of Clinical...
Case 3: Management of Multiply Relapsed DLBCL
This is Part 3 of Personalizing Treatment Pathways in Relapsed/Refractory DLBCL, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Jeremy Abramson, J. Erika Haydu, and Jacob Soumerai discuss the treatment of multiply relapsed...
Case 2: Second-Line Management of Relapsed DLBCL
This is Part 2 of Personalizing Treatment Pathways in Relapsed/Refractory DLBCL, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Jeremy Abramson, J. Erika Haydu, and Jacob Soumerai discuss the second-line treatment of relapsed ...
Case 1: Management of Early Relapsed DLBCL
This is Part 1 of Personalizing Treatment Pathways in Relapsed/Refractory DLBCL, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Jeremy Abramson, J. Erika Haydu, and Jacob Soumerai discuss the treatment of early relapsed...
Studies Move Away From Whole-Brain Radiotherapy Standard of Care for SCLC
When patients with small cell lung cancer (SCLC) progress, as is common with such an aggressive malignancy, brain metastasis is a known possibility. As such, guidelines have recommended prophylactic cranial irradiation for patients with SCLC who respond well to first-line therapy to decrease the...
Pirtobrutinib Improves Progression-Free Survival vs Bendamustine/Rituximab in Front-Line CLL/SLL
The first prospective, randomized phase III trial of a noncovalent Bruton’s tyrosine kinase (BTK) inhibitor exclusively in treatment-naive patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)—BRUIN CLL-313—demonstrated a statistically significant and clinically...
New Four-Biomarker Blood Panel May Improve Early Detection of Pancreatic Cancer
Pancreatic ductal adenocarcinoma is the most common form of pancreatic cancer, and is most often diagnosed at advanced, unresectable stages, when 5-year survival is just 3%. The results from two retrospective phase II studies investigating blood biomarkers to detect early-stage pancreatic ductal...
AI Tool May Predict Cardiac Events in Patients With Cancer and Acute Coronary Syndrome
An artificial intelligence (AI)-based risk prediction model, ONCO-ACS, showed possible favorable clinical utility as a practical tool for predicting cardiovascular death, myocardial infarction, and ischemic stroke events in patients with cancer and acute coronary syndrome, according to findings...
Overall Survival With 3 vs 6 Months of Adjuvant Oxaliplatin Plus Fluoropyrimidine for Colorectal Cancer
As reported in the Journal of Clinical Oncology by Iveson et al, final results of the UK-based noninferiority phase III SCOT trial have shown noninferiority of 3 vs 6 months of adjuvant oxaliplatin plus fluoropyrimidine chemotherapy in overall survival among patients with colorectal cancer....
Adjuvant Aumolertinib in EGFR-Mutated NSCLC
As reported in The Lancet Oncology by Zhang et al, the Chinese phase III ARTS trial showed superior disease-free survival with the third-generation EGFR tyrosine kinase inhibitor aumolertinib as adjuvant therapy vs placebo in patients with completely resected stage II to IIIB EGFR-mutated non–small ...
Jame Abraham, MD, FACP, on T-DXd in HER2-Positive Early Breast Cancer: Follow-up Data
Jame Abraham, MD, FACP, discusses follow-up data from the DESTINY Breast-05 and DESTINY Breast-11 trials of fam-trastuzumab deruxtecan-nki (T-DXd) for HER2-positive early breast cancer. DESTINY Breast-05 examined the agent given postneoadjuvantly, while DESTINY Breast-11 evaluated the agent in a...
Jame Abraham, MD, FACP, on a Novel Oral SERD for ER-Positive, HER2-Negative Early Breast Cancer
Jame Abraham, MD, FACP, discusses the global, randomized lidERA Breast Cancer trial. Results from lidERA position giredestrant as a potential new standard of care for patients with estrogen receptor (ER)-positive, HER2-negative stage I to III early breast cancer, marking the first phase III trial...
Responses to Initial Pembrolizumab Support Treatment De-escalation in Cutaneous Squamous Cell Carcinoma
A response-adapted approach to treatment decision-making for patients with resectable cutaneous squamous cell carcinoma demonstrated that with the use of neoadjuvant pembrolizumab, many patients could avoid surgery and/or radiotherapy. Findings from the De-Squamate study were published in the...
Novel HER2-Targeted Bispecific Benefits Outcomes in Gastroesophageal Cancer
In patients with advanced HER2-positive gastroesophageal adenocarcinoma, treatment with the bispecific antibody zanidatamab-hrii and chemotherapy, with or without the PD-1 inhibitor tislelizumab-jsgr, reduced the risk of disease progression or death by 35% over trastuzumab plus chemotherapy in the...
Deep-Learning CT Biomarker Predicts Survival Better Than Traditional Measures in Immunotherapy-Treated Advanced NSCLC
Sako et al conducted a prognostic study to evaluate whether a fully automated deep-learning radiomic biomarker based on serial CT scans could improve prediction of overall survival in patients with advanced non–small cell lung cancer (NSCLC) receiving immune checkpoint inhibitors. Their findings,...
Head and Neck Cancer: How Does Genetic Ancestry Impact Tumor Genomics?
Genetic ancestry plays a key role in determining the behavior of head and neck tumors and may help explain why African American patients survive for half as long as their counterparts of European ancestry, according to a new review study published by Ndahayo et al in Cancer and Metastasis Reviews....
Randomized Trial Shows AI-Supported Mammography Improves Sensitivity and Lowers Interval Cancer Rate
A randomized, controlled clinical trial for artificial intelligence (AI)–supported mammography readings, called the MASAI trial, demonstrated that AI reads of mammogram scans led to fewer interval breast cancer diagnoses than with standard double reads by radiologists, according to findings...
AACR Announces Fellows of the AACR Academy Class of 2026
The American Association for Cancer Research (AACR) has announced its newly elected 2026 class of Fellows of the AACR Academy. The Fellows of the AACR Academy was established to honor scientists, clinicians, and physician-scientists whose visionary work has reshaped the landscape of cancer...
Ultrasound-Guided DOT May Reduce Unnecessary Breast Biopsies by Nearly 25%
A team of researchers and physicians found that utilizing ultrasound-guided diffuse optical tomography (DOT) technology may reduce unnecessary breast biopsy rates by nearly 25%. Using this new method first—rather than starting with a biopsy—may help to determine if additional diagnoses are needed...
Adjuvant Durvalumab in Resected Early-Stage NSCLC
In a phase III trial (Canadian Cancer Trials Group BR.31) reported in the Journal of Clinical Oncology, Goss et al found that adjuvant durvalumab did not improve disease-free survival vs placebo in patients with completely resected early-stage non–small cell lung cancer (NSCLC). Study Details In...
Extended Endocrine Therapy in Premenopausal Patients With Node-Positive, Hormone Receptor–Positive Breast Cancer
In a cohort study analysis reported in the Journal of Clinical Oncology, Valenza et al found that extended endocrine therapy after 5 years of adjuvant luteinizing hormone–releasing hormone agonist (LHRHa) treatment was associated with benefit among premenopausal women with node-positive, hormone...
Consensus Recommendations Developed for Use of Liquid Nitrogen Spray Cryotherapy in Barrett's Esophagus, Esophageal Cancer
The Spray Cryotherapy Esophageal Consortium has developed a set of expert and evidence-based consensus recommendations guiding the use of liquid nitrogen spray cryotherapy in Barrett's esophagus and esophageal cancer. The recommendations, decided upon through a modified Delphi process, were...
Machine Learning–Enhanced Prognostic Scoring Predicts Survival and Classifies Risk From Spinal Metastases
A prognostic scoring system for predicting 1-year survival in patients with advanced cancer and spinal metastases was enhanced with machine learning for greater accuracy, according to the results of a Japanese multicenter study published in Spine. "This model provides a practical risk assessment...
American College of Surgeons Publishes Annual NCDB Report
The second annual report from the National Cancer Database (NCDB) of the American College of Surgeons (ACS) documents a substantial rise in neoadjuvant treatments, such as chemotherapy, immunotherapy, and hormone therapy, often allowing for less invasive surgery and helping clinicians assess how a...
Advanced NSCLC: Dual vs Single Checkpoint Blockade
A global meta-analysis combined detailed patient data from six major clinical trials to compare two types of immunotherapies for advanced non–small cell lung cancer (NSCLC): dual immunotherapy (a combination of CTLA-4 and PD-1/PD-L1 inhibitors) and single immunotherapy (PD-1/PD-L1 inhibitors...
Updated Analysis of CARTITUDE-4: Ciltacabtagene Autoleucel in Lenalidomide-Refractory Multiple Myeloma
As reported in The Lancet Oncology by Einsele et al, an updated analysis of the phase III CARTITUDE-4 trial has shown that a single infusion of ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen–directed chimeric antigen receptor (CAR) T-cell therapy, prolonged overall survival vs...
